Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04419402|
Recruitment Status : Recruiting
First Posted : June 5, 2020
Last Update Posted : October 1, 2021
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Castration-Resistant Prostate Cancer||Drug: Lu-PSMA Drug: Enzalutamide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)|
|Actual Study Start Date :||August 17, 2020|
|Estimated Primary Completion Date :||June 1, 2022|
|Estimated Study Completion Date :||June 1, 2023|
Experimental: Lu-PSMA + Enzalutamide
Lu-PSMA - 7.5 GBq (± 10%): doses 1 and 2 (Days 15 and 57). Doses 3 and 4 (Days 113 and 169) will be given following result of PSMA PET/CT scans at Day 92.
Enzalumatide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity.
Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.
Treatment administered every 6 weeks, x 4 cycles.
Other Name: 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA
160 mg (four 40 mg capsules) daily.
Other Name: Xtandi
Active Comparator: Enzalutamide
Enzalutamide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity.
160 mg (four 40 mg capsules) daily.
Other Name: Xtandi
- Prostate Specific Antigen (PSA) Progression-Free Survival [ Time Frame: Date of randomisation to the date of first evidence of PSA progression - assessed up to study completion, approximately 4 years from recruitment. ]PSA progression is defined as a rise in PSA by more than or equal to 25% AND more than or equal to 2 ng/mL above the nadir (lowest PSA point). This needs to be confirmed by a repeat PSA performed at least 3 weeks later.
- Radiographic Progression-Free Survival [ Time Frame: Date of randomisation to the date of first evidence of radiographic progression on imaging. Assessed every 12 weeks through study completion, approximately 4 years from start of recruitment. ]Radiographic progression-free survival is defined as the interval from the date of randomisation to the date of first evidence of radiographic progression on imaging, or the date of last known follow-up without progression.
- Prostate Specific Antigen (PSA) response rate [ Time Frame: Date of randomisation through study completion, approximately 4 years from start of recruitment. Early rises in PSA prior to 12 weeks will be disregarded in determining PSA response ]PSA response rate is defined as the proportion of participants in each group with a PSA reduction of 50% or more from baseline.
- Pain response and Progression-Free Survival [ Time Frame: Date of randomisation through study completion, approximately 4 years from start of recruitment ]
Pain is measured using the McGill-Melzack Present Pain Intensity scale (PPI). Pain Response is defined as a reduction of 2 or more points for participants with a baseline PPI score of 2 or more. Pain progression is defined as and an increase of 1 or more points in the nadir PPI score.
Pain Response is defined as a reduction of 2 or more points for participants with a baseline PPI score of 2 or more.
Pain progression is defined as and an increase of 1 or more points in the nadir PPI score.
- Clinical Progression-Free Survival [ Time Frame: Date of randomisation to the date of first clinical evidence of disease progression or death from any cause. Assessed up to study completion approximately 4 years from recruitment. ]Clinical progression is defined by progression on imaging, development of symptoms attributable to cancer progression, the need for radiotherapy to new metastases or initiation of other anticancer treatment for prostate cancer.
- Aspects of Health-related Quality of life (HRQL) [ Time Frame: Assessed every 4-6 weeks, through study completion, approximately 4 years from recruitment. ]The European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire includes five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), and a global health and quality-of-life scale to assess HRQL in cancer patients. The Patient DATA form is a simple, multi-item quality of life instrument based on 11-point numeric rating scales for a range of relevant symptoms and functions. It combines cancer specific items from the UBQ-C, GLQ-8 and LASA cancer-specific quality of life instruments. The Fear of Cancer Progression form is a short questionnaire assessing possible future concerns related to the participant's illness.
- Frequency and Severity of Adverse Events [ Time Frame: Through study completion, approximately 4 years from recruitment. ]The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to classify and grade the intensity of adverse events during study treatment.
- Overall Survival [ Time Frame: Through study completion, approximately 4 years from recruitment. ]Overall survival is defined as the interval from date of randomisation to the date of death from any cause, or the date of last known follow-up alive.
- Resource Use and Incremental Cost-effectiveness [ Time Frame: Through study completion, approximately 4 years from recruitment. ]Information on health-care resource use will be combined with information on overall survival and quality of life to estimate the value associated with the addition of Lu-PSMA to enzalutamide in terms of the cost per Quality adjusted life year (QALY).
- Association between Clinical Outcomes and Imaging Analyses at Baseline and During Treatment [ Time Frame: Through study completion, approximately 4 years from recruitment. ]A variety of methods to develop, validate and compare predictive and prognostic biomarkers for both enzalutamide treatment and enzalutamide and Lu-PSMA therapy. These include but are not limited to analyses of: 1. associations of screening whole body quantitative parameters on 68Ga-PSMA PET/CT and 18F FDG PET/CT; 2. association between the change on whole body quantitative PET parameters; 3. using the 68Ga-PSMA PET/CT at Day 92, assessment of quantitative whole body PET findings will help determine the proportion of men with persistent PSMA avid disease volume in those undergoing either enzalutamide or enzalutamide and Lu-PSMA treatments; 4. a visual scoring system for both 68Ga-PSMA PET/CT and 18F FDG PET/ CT to evaluate and validate its use in treatment response; 5. QTBI (Quantitative total body imaging) heterogeneity assessment.
- Association between Clinical Outcomes and Possible Prognostic/Predictive Biomarkers (tissue and circulating) including CTCs and ctDNA [ Time Frame: Through to study completion, approximately 4 years from recruitment. ]Translational research will include identifying tissue and circulating biomarkers that are prognostic and/or predictive of response to treatment, safety and resistance to study treatment (associations of biomarkers with clinical outcomes). These include, but are not limited to analyses of: 1. Liquid biopsies: Liquid biopsies will be collected at molecular imaging time points including at baseline, Day 92 and at first progression; 2. CTC: CTCs may be enumerated and analysed at the above time points for a variety of biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04419402
|Contact: Margaret McJannett||+6129562 email@example.com|
|Contact: Jenna Mitchellfirstname.lastname@example.org|
|Australia, New South Wales|
|Chris O'Brien Lifehouse||Recruiting|
|Camperdown, New South Wales, Australia, 2050|
|Contact: Lisa Horvath email@example.com|
|St Vincents Hospital||Recruiting|
|Darlinghurst, New South Wales, Australia, 2010|
|Contact: Louise Emmett, MBBS, FRACP firstname.lastname@example.org|
|Contact: Andrew Nguyen, MBBS, FRACP email@example.com|
|Principal Investigator: Anthony Joshua, MBBS FRACP|
|Liverpool, New South Wales, Australia, 2170|
|Contact: Wei Chua Wei.Chua@health.nsw.gov.au|
|Contact: Peter Lin Peter.Lin1@health.nsw.gov.au|
|Calvary Mater Newcastle||Recruiting|
|Newcastle, New South Wales, Australia, 2298|
|Contact: Craig Gedye firstname.lastname@example.org|
|Contact: Natalie Rutherford|
|Northern Cancer Institute||Recruiting|
|Sydney, New South Wales, Australia, 2065|
|Contact: Laurence Krieger|
|Royal Brisbane and Women's Hospital||Recruiting|
|Brisbane, Queensland, Australia, 4029|
|Contact: Jeff Goh Jeffrey.Goh@health.qld.gov.au|
|Contact: David Pattison David.Pattison@health.qld.gov.au|
|Australia, South Australia|
|Royal Adelaide Hospital||Recruiting|
|Adelaide, South Australia, Australia, 5000|
|Contact: Hsiang Tan, MBBS FRACP +61 7074 2336 email@example.com|
|Contact: Ian Kirkwood, MBBS FRACP (08) 7074 0283 Ian.Kirkwood@sa.gov.au|
|Clayton, Victoria, Australia, 3168|
|Contact: David Pook firstname.lastname@example.org|
|Contact: Shakher Ramdave Shakher.Ramdave@monash.edu|
|Heidelberg, Victoria, Australia, 3084|
|Contact: Andrew Weickhardt, MBBS, FRACP +61 39496 5763 email@example.com|
|Contact: Sze Ting Lee, MBBS, FRACP +61 39496 3063 SzeTing.LEE@austin.org.au|
|Principal Investigator: Andrew Weickhardt, MBBS, FRACP|
|Principal Investigator: Sze Ting Lee, MBBS, FRACP|
|Peter MacCallum Cancer Centre||Recruiting|
|Melbourne, Victoria, Australia, 3002|
|Contact: Shahneen Sandhu, MBBS FRACP Shahneen.Sandhu@petermac.org|
|Contact: Michael Hofman, MBBS, FRACP Michael.Hofman@petermac.org|
|Principal Investigator: Aravind R Kumar, MBBS, FRACP|
|The Alfred Hospital||Recruiting|
|Melbourne, Victoria, Australia, 3004|
|Contact: Mark Voskoboynik firstname.lastname@example.org|
|Contact: David Nadebaum D.Nadebaum@alfred.org.au|
|Australia, Western Australia|
|Sir Charles Gairdner Hospital||Recruiting|
|Nedlands, Western Australia, Australia, 6009|
|Contact: Dr Siobhan Ng email@example.com|
|Contact: A/Prof Roslyn Francis Ros.Francis@health.wa.gov.au|
|Fiona Stanley Hospital||Recruiting|
|Perth, Western Australia, Australia, 6150|
|Contact: Andrew Redfern Andrew.Redfern@health.wa.gov.au|
|Study Chair:||Louise Emmett, MBBS, FRACP||St Vincent's Hospital, Sydney|